Company Filing History:
1 out of 94 
1 out of 93 
Years Active: 2011
Title: The Innovative Contributions of Isabelle Camby
Introduction
Isabelle Camby is a notable inventor based in Tubize, Belgium. She has made significant strides in the field of cancer treatment through her innovative research and development. Her work focuses on utilizing RNA interference (RNAi) technology to target galectin-1, a protein implicated in various cancers.
Latest Patents
Isabelle Camby holds a patent for the "Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer." This invention relates to an RNAi molecule designed to reduce the expression of galectin-1, specifically utilizing sequences from SEQ ID NOs: 1-33, with a preference for SEQ ID NOs: 2, 3, or 4. The patent outlines its application as a medicament for treating or delaying the progression of several types of cancer, including glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer, and non-Hodgkin's lymphoma. Additionally, it discusses methods for reducing tumor cell migration and enhancing the efficacy of various cancer therapies.
Career Highlights
Throughout her career, Isabelle has worked with prestigious institutions, including Université Libre de Bruxelles and Université Catholique de Louvain. Her research has contributed to advancements in cancer therapies, showcasing her commitment to improving patient outcomes.
Collaborations
Isabelle Camby has collaborated with notable colleagues such as Patrick Henriet and Florence Lefranc. These partnerships have further enriched her research and development efforts in the field of oncology.
Conclusion
Isabelle Camby's innovative work in RNAi-based cancer treatment exemplifies her dedication to advancing medical science. Her contributions are paving the way for new therapeutic approaches in oncology, ultimately aiming to improve the lives of patients battling cancer.